Annualized recurring revenue ('ARR”) of $840 millionFull-year revenue of $860 million, increased 2% year-over-yearFull-year net cash provided by operating activities of $154 million; free cash flow of ...
Payment schedules, such as a month-to-month option, provide more flexibility, especially during periods of low cash flow. Make sure the pricing structure is transparent, and opt for a month-to-month ...
In the Cleats & Cashflows section, we look at the opportunities offered by private equity, but also at the risks involved.
The Consolidated Appropriations Act of 2026 acts as a first step in addressing prescription drug pricing challenges related to the role of pharmacy benefit managers (PBMs).